Safety and efficacy of tivozanib–nivolumab combination in patients with metastatic kidney cancer

In this phase 1b/2 study the researchers looked at a combination of tivozanib and nivolumab in 25 patients with metastatic renal cell carcinoma (RCC). Tivozanib is a targeted therapy called a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) that blocks the growth of blood vessels to the tumour, while nivolumab is an immune […]

read more

Cabozantinib plus atezolizumab as first-line treatment for advanced kidney cancer

Clinical trial, COSMIC-021, investigated a combination of cabozantinib and atezolizumab in untreated clear-cell renal cell carcinoma (RCC). There were two groups of patients; one on 60 mg of cabozantinib plus the standard dose of atezolizumab, and the other on 40 mg cabozantinib plus atezolizumab. The results were similar between the two doses and the time […]

read more

Cabozantinib plus atezolizumab for non-clear cell renal cell carcinoma

In this video interview with Dr Monty Pal from the City of Hope Hospital in California, treatment of non-clear cell renal cell carcinoma (RCC) with a combination of cabozantinib plus atezolizumab is discussed. Most research is focussed on clear cell RCC; however, non-clear cell RCC accounts for about 25% of all RCC diagnoses and usually […]

read more

Treatment selection for metastatic kidney cancer based on gene expression

The discovery of a reliable biomarker for metastatic renal cell carcinoma (RCC) to predict response to treatment has been difficult to identify. This study was presented at the European Society of Medical Oncology (ESMO) Virtual Congress in September this year. The interview started by describing the currently used scoring systems used to categorise patients into […]

read more

ESMO Virtual 2020: Impact of immunotherapy on quality of life

In this video interview, Dr Jeffrey Kirshner from the Haematology-Oncology Associates of Central New York Community Clinical Oncology Programme talks about a global review of data on quality of life in patients on immunotherapy that was presented at this year’s ESMO.  During the interview, Dr Kirshner mentions that quality of life is better with immunotherapy than […]

read more

Surgery after targeted therapy or immunotherapy for metastatic kidney cancer

A recent retrospective study (looking back at the patients’ cases after treatment had occurred) has shown that patients with metastatic renal cell carcinoma (RCC) who were treated with targeted therapy, such as sunitinib or pazopanib, or immunotherapy, such as nivolumab, had better survival outcomes if went on to have surgery to remove the kidney. This […]

read more

ESMO Virtual 2020: Quality of life impact of immune checkpoint inhibitors

Immune checkpoint inhibitors have changed the way renal cell carcinoma (RCC) is treated and may improve quality of life. During a presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 last week the results from a large analysis of the use of immune checkpoint inhibitors in different cancers was presented. The study […]

read more

ESMO Virtual 2020: Biomarker-guided therapy in metastatic kidney cancer

Yesterday, findings from the phase 2 biomarker trial, BIONIKK, were presented at the European Sociaety of Medical Oncology (ESMO) virtual congress. The study showed clinical evidence that biomarker-guided first-line therapy could be used to enrich responses in patients with metastatic clear cell renal cell carcinoma (RCC). The trial included 154 patients treated with nivolumab or […]

read more

ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer

Non-clear cell renal cell carcinoma (RCC) accounts for about 25% of all RCC diagnoses and usually has worse outcomes than clear cell RCC. Both cabozantinib and immune checkpoint inhibitors have shown preliminary activity in non-clear cell RCC. Cabozantinib appears to enhance the response to immune checkpoint inhibitors and has shown encouraging results in combination with […]

read more

ESMO Virtual 2020: Nivolumab plus cabozantinib for first-line advanced kidney cancer

At the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Dr Choueiri from Dana Farber Cancer Institute in Boston, USA presented the results of the phase 3 CheckMate-9ER trial evaluating the combination of nivolumab and cabozantinib compared to sunitinib in the first-line treatment of patients with advanced or metastatic renal cell carcinoma (RCC). Each […]

read more
Showing 1 to 10 of 174 results
  TOP